ClinicalTrials.gg
CompletedNCT01844648Updated Dec 10, 2015

Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients

A Phase 2 interventional study of NH004 tropicamide and NH004 Placebo in Sialorrhea (Excessive Drooling), sponsored by NeuroHealing Pharmaceuticals Inc.. Completed at 3 sites in France. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.

Sponsored by NeuroHealing Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

To study the safety and efficacy of tropicamide 1 mg intra-oral slow dissolving muco-adhesive thin films compared to placebo to reduce hypersalivation in PD patients manifesting sialorrhea complaints.

Read the detailed description

This is a double-blind, placebo-controlled, randomized, crossover, multicentre study comparing intra-oral slow dissolving muco-adhesive thin films containing tropicamide 1 mg or Placebo. Patients will receive each treatment twice daily (1 h after breakfast and 1 h after lunch) for 1-week.

Patients will be evaluated for eligibility during the 14-day screening period. Those patients meeting all entry criteria at baseline will be randomized (1:1) to receive first tropicamide followed by placebo films or vice versa. Patients will return for regularly scheduled visits at Weeks 1 and 3 or at early discontinuation.

02

Conditions studied

  • Sialorrhea (Excessive Drooling)

Keywords

  • Parkinson's disease
  • Sialorrhea
  • Tropicamide
  • Non-motor symptoms
  • Thin strip delivery
03

In context

Sialorrhea

60 studies on the registry are indexed under Sialorrhea; 5 are open to participants now.

This study's enrollment of 30 is close to the median of 31 across 44 interventional studies indexed under Sialorrhea.

Browse Sialorrhea studies →

Lead sponsor

NeuroHealing Pharmaceuticals Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with idiopathic Parkinson's disease, according to the UK Brain Bank criteria.
  • Patients complaining of drooling, with a score of at least 6 points in the SCS-PD scale.
  • Patients above 30 years old.
  • Patients with Hoehn \& Yahr score between I-IV.
  • Male or non-pregnant female. Females of will be required to have undergone a pregnancy test with negative results prior to entry to the study and agree to use measures for the duration of the study.
  • Patients must have used the same antiparkinsonian medications and at the same dose for the last month. No changes in the medication for PD are expected during the study.

Exclusion criteria

Exclusion criteria:

  • Pregnant women.
  • Patients with a secondary parkinsonian syndrome, parkinsonism-plus syndromes, heredodegenerative disorders or benign parkinsonism.
  • Patients with a diagnosis of major depression or psychosis according to the .
  • Patients with score equal to or lower than 24.
  • Patients with a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months.
  • Patients with hallucinations.
  • Patients with a current gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including hypertension that is not well-controlled, asthma, (COPD) and Type I diabetes.
  • Patients with a second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or significant abnormality, including ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method.
  • Patient with a neoplastic disorder, which is either currently active or has been in remission for less than one year.
  • Patients with a history or a current diagnosis of , or tests positive for or C antibodies, or Hepatitis B surface antigen
  • Patients who have participated in a previous clinical trial within 30 days of entry into the study (screening visit) or have received treatment with any compound within 30 days.
  • Patients with to atropine or other anticholinergic drugs.
  • Patients who have experienced adverse effects as a result of taking anticholinergic drugs.
  • Patients who are receiving any anticholinergic drug or an anticholinesterase agent.
  • Patients who started or changed the dose of any of the following medications in the previous week: tricyclic antidepressants, monoamine oxidase-A inhibitors, antipsychotics, benzodiazepines, opioids, antihistamines, carbamazepine, NSAIDs.
  • Patients with significant dental/oral pathology.
  • Patient with any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in a diagnostic laboratory test.
  • Patients with closed-angle Glaucoma or those at high risk of suffering it after treatment with anticholinergic agents.
  • Patients with Prostatic Adenoma.
  • In the judgment of the Clinical Investigator, the patient is likely to be non-compliant or uncooperative during the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    NH004 tropicamide

    tropicamide 1 mg thin film, twice daily for 7 days

    Drug: NH004 tropicamide

  • Placebo comparator
    NH004 placebo

    placebo thin film, twice daily for 7 days

    Drug: NH004 Placebo

Interventions

  • DrugNH004 tropicamide

    Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide

  • DrugNH004 Placebo

    Intra-oral slow dissolving muco-adhesive thin film

06

What researchers measure

Primary outcomes

  1. modified Teachers Drooling Scale (% responding)

    The primary endpoint for this trial is the difference in responder rate between tropicamide and placebo. Responders will be defined as subjects whose mean sialorrhea score improved by at least 30% as compared to baseline in the 9-point modified Teachers Drooling Scale (mTDS).

    Time frame: one week

Secondary outcomes

  1. modified Teachers Drooling Scale (mean)

    Difference in the mean sialorrhea scores between placebo and tropicamide in the 9-point modified Teachers Drooling Scale (mTDS).

    Time frame: one week

  2. Sialorrhea Clinical Scale for Parkinson's Disease (mean)

    - Difference in the mean sialorrhea scores between placebo and tropicamide in the Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD).

    Time frame: one week

  3. UPDRS Part II sialorrhea item (mean)

    Difference in the mean sialorrhea scores between placebo and tropicamide in the UPDRS Part II sialorrhea item (#6).

    Time frame: one week

  4. Visual Analg Scale

    Saliva buccal content as measured by a Visual Analog Scale (VAS) score, evaluated before and during 3 hours after treatments administration.

    Time frame: one week

07

Study locations

3 sites
  • Hôpital de la Salpêtrière
    Paris, Cedrex 13 75651, France
  • Hôpital Paul de Viguier
    Toulouse, Cedrex 9 31059, France
  • Hôpital Haut Lévêque
    Bordeaux, Pessac 33604, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01844648
Lead sponsor
NeuroHealing Pharmaceuticals Inc.
Collaborators
Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Apr 2013
Primary completion
Oct 2015
Completion
Dec 2015
Last update
Dec 10, 2015

Study contacts

Elkan R Gamzu, PhD
study director · NeuroHealing Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion